Elevating Digital PCR: QIAGEN's Latest Innovations
QIAGEN has recently unveiled impressive enhancements to its QIAcuity Digital PCR system, optimizing its high-order multiplexing capabilities. This advancement enables researchers to derive richer insights from biological samples, pushing the boundaries of current molecular biology techniques.
More Targets, More Insights
With the new software upgrade and the introduction of the QIAcuity High Multiplex Probe PCR Kit, users can analyze up to 12 targets simultaneously from a single biological sample. This significant increase from the previous limit of five targets allows researchers to maximize the efficiency of their experiments.
Applications Across Science
QIAGEN's QIAcuity system is increasingly recognized for its ability to tackle various important applications. From translational research to microbiome analysis and pathogen detection, the versatility of this digital PCR technology is enhancing research capabilities in multiple fields.
Streamlined Processes for Deeper Understanding
The flexibility of QIAcuity addresses existing challenges in assay design found in current quantitative multiplex PCR offerings. By combining multiple PCR assays, researchers can not only use their samples more effectively but also conserve valuable resources, ultimately speeding up the timeline for gaining deep biological insights.
Expert Insights from QIAGEN
Nitin Sood, Senior Vice President and Head of the Life Sciences Business Area at QIAGEN, highlighted the importance of these developments, stating that increasing the number of analyzable targets from a single sample is a critical advancement in making QIAcuity the preferred choice for groundbreaking dPCR applications.
Robust Adoption and Community Engagement
By the end of 2024, QIAGEN reported over 2,700 placements of its QIAcuity digital PCR instruments and over 550 citations in scientific publications. This robust adoption underscores the trust that pharmaceutical companies, biotechnology firms, and academic organizations place in QIAGEN's technology.
Future Developments in Clinical Testing
In a strategic move to expand its reach into clinical testing, QIAGEN launched the QIAcuityDx in the fall of 2024. This initiative is tailored to meet the needs of clinical customers, providing further choices within the QIAcuity product line.
The Power of the QIAcuity High Multiplex Probe PCR Kit
The new High Multiplex Probe PCR Kit comes with a ready-to-use master mix specifically optimized for microfluidic applications in QIAcuity Nanoplates. This kit not only expands accessibility for high-order multiplexing but also enhances the specificity and efficiency of digital PCR methods.
Advanced Software Features for Enhanced Analysis
Essential updates in the QIAcuity Software 3.1 introduce crucial features for high-order multiplexing, including crosstalk compensation. This functionality corrects any signal overlap between targets, enabling researchers to analyze a broader array of targets confidently.
Customized Assays for Diverse Needs
QIAGEN has revamped its dPCR catalog and custom assays to support up to 12-plex reactions, broadening its capabilities in copy number variation (CNV) analysis and microbial detection. Users can access these innovative solutions through QIAGEN's GeneGlobe platform, further exemplifying the SNP technology's versatility.
Combining Software and Chemistry for Optimal Results
The integration of sophisticated software with advanced chemistry positions QIAcuity dPCR as a leading solution for high-order multiplexing. Researchers benefit from enhanced workflows featuring increased target capacity and improved data accuracy, making QIAcuity the high-throughput choice in the digital PCR landscape.
Innovative Platform Design
The QIAcuity platform efficiently disperses samples into thousands of micro-partitions, allowing for simultaneous quantification of DNA and RNA signals, even at low concentrations. This innovation integrates critical processes—partitioning, thermocycling, and imaging—into a streamlined workflow, slashing processing times from six hours to just two.
Availability Across Diverse Laboratory Needs
Designed to cater to a wide range of laboratory sizes and throughput requirements, the QIAcuity platform is available in one-, four-, and eight-plate versions, ensuring that researchers can find a solution that fits their specific needs.
Frequently Asked Questions
What is the key feature of QIAGEN's QIAcuity Digital PCR system?
The QIAcuity system now allows for the simultaneous analysis of up to 12 targets from a single biological sample, which is a tremendous upgrade from the previous maximum of five targets.
Who can benefit from QIAcuity's multiplexing capabilities?
Researchers in various fields, including translational research, microbiome studies, and clinical testing, can greatly benefit from these enhanced capabilities.
What applications can the QIAcuity system support?
The QIAcuity system supports a variety of applications such as pathogen detection, development of cell and gene therapies, and copy number variation analysis.
How does the High Multiplex Probe PCR Kit enhance research?
This kit optimizes assay performance, increases specificity, and allows for high-order multiplexing without requiring additional hardware investments.
Can QIAcuity users conduct clinical tests?
Yes, with the introduction of the QIAcuityDx, users can conduct clinical testing to meet specific customer segment needs in clinical settings.
